Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
46.67
-0.75 (-1.58%)
At close: Dec 5, 2025, 4:00 PM EST
46.60
-0.07 (-0.15%)
After-hours: Dec 5, 2025, 5:48 PM EST
Crinetics Pharmaceuticals Employees
Crinetics Pharmaceuticals had 437 employees as of December 31, 2024. The number of employees increased by 147 or 50.69% compared to the previous year.
Employees
437
Change (1Y)
147
Growth (1Y)
50.69%
Revenue / Employee
$3,513
Profits / Employee
-$968,185
Market Cap
4.43B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRNX News
- 2 days ago - Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors - GlobeNewsWire
- 8 days ago - Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year - The Motley Fool
- 15 days ago - Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome - GlobeNewsWire
- 25 days ago - Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Why Crinetics Pharmaceuticals Stock Was Sliding on Friday - The Motley Fool
- 4 weeks ago - Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting - GlobeNewsWire